

TABLE. WET AMD TREATMENT PIPELINE					
Drug (Company)	Mechanism	NCT #	Estimated Study Completion	Recruitment Status	Last Update Posted
PHASE I					
OTX-TKI (Ocular Therapeutix)	Intravitreal implant with tyrosine kinase inhibitor	NCT03630315	December 2022	Active, not recruiting	August 2022
R07250284 (Hoffman-La Roche)	Bispecific human antigen-binding fragment of faricimab via the port delivery system	NCT04567303	November 2025	Recruiting	November 2022
BD311 (BDGene Co)	Gene therapy	NCT05099094	September 2023	Recruiting	August 2022
AIV007 (AiViva BioPharma)	Intravitreal gel suspension	NCT04422899	Complete		May 2022
MHU650 (Novartis)	Intravitreal injection	NCT04635800	Complete		September 2022
AR-13503 (Aerie)	Rho kinase inhibitor sustained release intravitreal implant	NCT03835884	Complete		June 2022
ASKG712 (AskGene Pharma)	Anti-VEGF antibody and ang-2 antagonist fusion protein	NCT05456828	April 2024	Not yet recruiting	July 2022
PHASE II					
IBI302 (Innovent Biologics)	Intravitreal injection of a bispecific fusion protein	NCT05403749	June 2024	Not yet recruiting	June 2022
UBX1325 (Unity Biotechnology)	Intravitreal injection of a Bcl-xL inhibitor	NCT05275205	January 2023	Active, not recruiting	May 2022
AXT107 (Asclepix Therapeutics)	Intravitreal self-assembling depot	NCT04746963	Complete		November 2022
4D-150 (4D Molecular Therapeutics)	Dual-transgene intravitreal gene therapy	NCT05197270	September 2026	Recruiting	October 2022
GB-102 (GrayBug Vision)	Intravitreal injection with sunitinib	NCT03953079	Complete		January 2022
EYP-1901 (EyePoint Pharmaceuticals)	Intravitreal implant with a tyrosine kinase inhibitor	NCT05381948	December 2023	Recruiting	August 2022
D-4517.2 (Ashvattha Therapeutics)	Intravitreal tyrosine kinase inhibitor	NCT05387837	May 2023	Recruiting	September 2022
CLS-AX (Clearside Biomedical)	Suprachoroidal injection of a tyrosine kinase inhibitor	NCT04626128	Complete		July 2022
PAN-90806 (PanOptica)	Topical tyrosine kinase inhibitor topical drop	NCT03479372	Complete		July 2019
MG-O-1002 (Theratocular Biotech)	Topical ophthalmic drop	NCT05390840	February 2023	Not yet recruiting	May 2022
AKST4290 (Alkahest)	Oral CCR3 inhibitor	NCT04331730	Complete		October 2021
RBM-007 (Ribomic)	Anti-fibroblast growth factor 2 aptamer intravitreal injection	NCT04895293	Complete		August 2022
Ixoberogene soroparvovec (formerly ADVM-022, Adverum Biotechnologies)	Intravitreal gene therapy	NCT05536973	February 2024	Recruiting	September 2022
RGX-314 (Regenxbio)	Suprachoroidal gene therapy	NCT04514653	January 2024	Recruiting	October 2023
PHASE III					
OPT-302 (Opthea)	Fc-fusion protein	NCT04757610, NCT04757636	December 2024	Recruiting	September 2022
KSI-301 (Kodiak Sciences)	Antibody biopolymer conjugate	NCT04964089	April 2023	Active, not recruiting	June 2022
RGX-314 (Regenxbio)	Subretinal gene therapy	NCT04704921, NCT05407636	March 2024 December 2024	Recruiting	May 2022 June 2022
BAT5906 (Bio-thera)	Recombinant anti-VEGF intravitreal injection	NCT05439629	June 2025	Not yet recruiting	June 2022